Hematopoietic stem cell transplantation market expansion is anticipated to be driven by the rising incidence of leukaemia and lymphoma over the course of the projected period. According to the Leukemia and Lymphoma Society's 2019 report, an estimated 176,200 Americans had leukaemia, lymphoma, or myeloma at the time of their diagnosis, and 1,399,180 of those people were still battling the disease. The need for hematopoietic stem cell transplantation is anticipated to rise in response to the rising incidence rate, fueling the market for hematopoietic stem cell transplantation (HSCT). In industrialised economies like the U.S. and Europe, lack of physical exercise, obesity, and/or poor nutrition are to blame for one-third of all cancer diagnoses (globally), according to the Global Cancer Research Fund's 2018 report. Leukemia also develops with age and affects people of middle age at a rate of about 90%. A growing number of HSCT transplants in the region is likely to cause Asia Pacific to see the fastest increase during the projection period.
According to Coherent Market Insights, The market for Hematopoietic Stem Cell Transplantation is anticipated to reach US$ 2,092.6 million in 2020 and grow at a CAGR of 11.2% during the following five years (2020-2027).
Leading Companies in the Hematopoietic Stem Cell Transplantation Industry:
1. Pluristem Therapeutics Inc.
The business was established in 2001 and is located in Haifa, Israel. The business is working to commercially produce human placental adherent stromal cells for the treatment of diseases. Pluristem started using placenta cells called PLX to treat COVID-19 patients in 2020. The application from Pluristem to carry out a Phase II trial with their PLX cells received approval from the US Food and Drug Administration on May 8, 2020.
2. CellGenix GmbH,
The business was established in 1994 and the business is headquartered in Freiburg, Germany. A vast variety of cell kinds, bioprocessing containers, and other medical supplements are available from the company, which also produces cell treatment and medications. To develop next-generation automated cell and gene therapy manufacturing platforms, such as Ori Biotech in May 2020, CellGenix is forming relationships with businesses in those industries.
3. Regen Biopharma Inc.
The business was founded in 2012 and has its headquarters in La Mesa, California, United States. The company's main objective is to build platforms for translational medicine that will enable the commercialization of stem cell treatments. Regen BioPharma, Inc. reported in October 2022 that it has filed a provisional patent for a CAR-T cell that may draw in and educate naive T cells to kill cancer.
4. Lonza Group
The business was founded in 1897 and has its headquarters in Basel, Switzerland. The business collaborates with clients in the healthcare industry to create, produce, and market medical products and technology that help patients fight a variety of ailments. Lonza Specialty Ingredients divested to Bain and Cinven in July 2021 for CHF 4.2 billion.
5. Kiadis Pharma
The business was established in 1997 and has its headquarters in Amsterdam, The Netherlands. The business focuses on the drawbacks and problems of hematopoietic stem cell transplants in patients with blood cancer while also developing and manufacturing biopharmaceutical goods.
6. Taiga Biotechnologies, Inc.
The business was founded in 2006 and is based in Aurora, Colorado, United States. The business is creating a new category of cell-based medicines that make use of allogeneic stem cells and autologous immune cells. The company is a biotechnology startup that is primarily interested in using the immune system's potential.
7. Bluebird Bio,
The business was established in 1992 and has its headquarters in Massachusetts, United States. The business offers gene therapy for severe genetic abnormalities such beta-thalassemia, neurodegenerative diseases, and paediatric cerebral adrenoleukodystrophy. Bluebird Bio, Inc. announced the upcoming separation of a new public firm 2seventy Bio with an oncology emphasis on October 8, 2021.
8. Talaris Therapeutics, Inc.
The business was established in 1988 and has its headquarters in Louisville, Kentucky, United States. The company focuses on creating its own allogeneic hematopoietic stem cell transplantation technique to treat patients with chronic immunosuppression, autoimmune illnesses, and benign blood, immunological, and metabolic abnormalities.
Definition: Hematopoietic stem-cell transplantation is the transplantation of multipotent hematopoietic stem cells, typically obtained from bone marrow, peripheral blood, or umbilical cord blood in order for them to multiply within a patient and produce more healthy blood cells.
